Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: Second edition

British Journal of Haematology

Volumn 159, Issue 5, 2012, Pages 528-540

  Watson, Henry ^a   Davidson, Simon ^b   Keeling, David ^c  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical haematology; Heparin; Heparin antibody; Heparin induced thrombocytopenia

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG INDICATION; DRUG INFUSION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY DIAGNOSIS; LABORATORY TEST; LOW DRUG DOSE; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS;

ANTICOAGULANTS; DISEASE MANAGEMENT; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 84869096127     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12059     Document Type: Article

References (92)

1. Alatri, A., Armstrong, A.E., Greinacher, A., Koster, A., Kozek-Langenecker, S.A., Lance, M.D., Link, A., Nielsen, J.D., Sandset, P.M., Spanjersberg, A.J. & Spannagl, M. (2012) Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thrombosis Research, 129, 426-433.
2. Aouifi, A., Blanc, P., Piriou, V., Bastien, O.H., Ffrench, P., Hanss, M. & Lehot, J.J. (2001) Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Annals of Thoracic Surgery, 71, 678-683.
3. Arepally, G.M. & Ortel, T.L. (2006) Clinical practice. Heparin-induced thrombocytopenia. New England Journal of Medicine, 355, 809-817.
4. Bakchoul, T., Giptner, A., Bein, G., Santoso, S. & Sachs, U.J. (2011) Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thrombosis Research, 127, 345-348.
5. Bartholomew, J.R. & Hursting, M.J. (2005) Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). Journal of Thrombosis and Thrombolysis, 19, 183-188.
6. Bryant, A., Low, J., Austin, S. & Joseph, J.E. (2008) Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. British Journal of Haematology, 143, 721-726.
7. Chong, B.H., Burgess, J. & Ismail, F. (1993) The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 69, 344-350.
8. Chong, B.H., Gallus, A.S., Cade, J.F., Magnani, H., Manoharan, A., Oldmeadow, M., Arthur, C., Rickard, K., Gallo, J., Lloyd, J., Seshadri, P. & Chesterman, C.N. (2001) Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thrombosis and Haemostasis, 86, 1170-1175.
9. Cuker, A., Arepally, G., Crowther, M.A., Rice, L., Datko, F., Hook, K., Propert, K.J., Kuter, D.J., Ortel, T.L., Konkle, B.A. & Cines, D.B. (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. Journal of Thrombosis and Haemostasis, 8, 2642-2650.
10. Dyke, C.M., Aldea, G., Koster, A., Smedira, N., Avery, E., Aronson, S., Spiess, B.D. & Lincoff, A.M. (2007) Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Annals of Thoracic Surgery, 84, 836-839.
11. Eichler, P., Budde, U., Haas, S., Kroll, H., Loreth, R.M., Meyer, O., Pachmann, U., Potzsch, B., Schabel, A., Albrecht, D. & Greinacher, A. (1999) First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thrombosis and Haemostasis, 81, 625-629.
12. Ekbatani, A., Asaro, L.R. & Malinow, A.M. (2010) Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. International Journal of Obstetric Anesthesia, 19, 82-87.
13. Farner, B., Eichler, P., Kroll, H. & Greinacher, A. (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 85, 950-957.
14. Fischer, K.-G. (2004) Haemodialysis in heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia (ed. by Warkentin T.E. & Greinacher A.), pp. 509-530. Marcel Dekker, New York.
15. Girolami, B., Prandoni, P., Stefani, P.M., Tanduo, C., Sabbion, P., Eichler, P., Ramon, R., Baggio, G., Fabris, F. & Girolami, A. (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood, 101, 2955-2959.
16. Goldfarb, M.J. & Blostein, M.D. (2011) Fondaparinux in acute heparin-induced thrombocytopenia: a case series. Journal of Thrombosis and Haemostasis, 9, 2501-2503.
17. Gray, E. & Harenberg, J., for the ISTH Control of Anticoagulation SSC Working Group on Thrombin Inhibitors (2005) Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. Journal of Thrombosis and Haemostasis, 3, 2096-2097.
18. Greer, I.A. & Nelson-Piercy, C. (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 106, 401-407.
19. Greinacher, A. (2011) Immunogenic but effective: the HIT-fondaparinux brain puzzler. Journal of Thrombosis and Haemostasis, 9, 2386-2388.
20. Greinacher, A. & Warkentin, T.E. (2004) Treatment of heparin-induced thrombocytopenia: an overview. In: Heparin-Induced Thrombocytopenia (ed. by T.E. Warkentin & A. Greinacher), pp. 335-370. Marcel Dekker, New York.
21. Greinacher, A., Michels, I., Kiefel, V. & Mueller-Eckhardt, C. (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thrombosis and Haemostasis, 66, 734-736.
22. Greinacher, A., Amiral, J., Dummel, V., Vissac, A., Kiefel, V. & Mueller-Eckhardt, C. (1994) Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion, 34, 381-385.
23. Greinacher, A., Eichler, P., Lubenow, N., Kwasny, H. & Luz, M. (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood, 96, 846-851.
24. Greinacher, A., Althaus, K., Krauel, K. & Selleng, S. (2010) Heparin-induced thrombocytopenia. Hamostaseologie, 30, 17-18. 20-28.
25. Hopkins, C.K. & Goldfinger, D. (2008) Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion, 48, 2128-2132.
26. Horsewood, P., Warkentin, T.E., Hayward, C.P. & Kelton, J.G. (1996) The epitope specificity of heparin-induced thrombocytopenia. British Journal of Haematology, 95, 161-167.
27. Jenkins, I., Helmons, P.J., Martin-Armstrong, L.M., Montazeri, M.E. & Renvall, M. (2011) High rates of venous thromboembolism prophylaxis did not increase the incidence of heparin-induced thrombocytopenia. Joint Commission Journal on Quality and Patient Safety, 37, 163-169.
28. Kato, S., Takahashi, K., Ayabe, K., Samad, R., Fukaya, E., Friedmann, P., Varma, M. & Bergmann, S.R. (2011) Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. British Journal of Haematology, 154, 373-377.
29. Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., Nelson, M.E., Wells, P.S., Gould, M.K., Dentali, F., Crowther, M. & Kahn, S.R. (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest, 141, e419S-e494S.
30. Keeling, D., Davidson, S. & Watson, H. (2006) The management of heparin-induced thrombocytopenia. British Journal of Haematology, 133, 259-269.
31. Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S. & Makris, M. (2011) Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology, 154, 311-324.
32. Kelton, J.G. (2005) The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest, 127, 9S-20S.
33. Keng, T.B. & Chong, B.H. (2001) Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. British Journal of Haematology, 114, 394-396.
34. Knol, H.M., Schultinge, L., Erwich, J.J. & Meijer, K. (2010) Fondaparinux as an alternative anticoagulant therapy during pregnancy. Journal of Thrombosis and Haemostasis, 8, 1876-1879.
35. Koster, A., Crystal, G.J., Kuppe, H. & Mertzlufft, F. (2000a) Acute heparin-induced thrombocytopenia type II during cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia, 14, 300-303.
36. Koster, A., Hansen, R., Kuppe, H., Hetzer, R., Crystal, G.J. & Mertzlufft, F. (2000b) Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. Journal of Cardiothoracic and Vascular Anesthesia, 14, 243-248.
37. Koster, A., Kukucka, M., Bach, F., Meyer, O., Fischer, T., Mertzlufft, F., Loebe, M., Hetzer, R. & Kuppe, H. (2001) Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology, 94, 245-251.
38. Koster, A., Dyke, C.M., Aldea, G., Smedira, N.G., McCarthy, II, H.L., Aronson, S., Hetzer, R., Avery, E., Spiess, B. & Lincoff, A.M. (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Annals of Thoracic Surgery, 83, 572-577.
39. Lee, D.H. & Warkentin, T.E. (2004) Frequency of heparin induced thrombocytopenia. In: Heparin Induced Thronbocytopenia (ed. by T.E. Warkentin & A. Greinacher), pp. 107-148. Marcel Dekker, New York.
40. Lewis, B.E., Wallis, D.E., Berkowitz, S.D., Matthai, W.H., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.K., Rifkin, S.D., Moran, J., Hursting, M.J., Kelton, J.G. & Investigators A.R.G.S. (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103, 1838-1843.
41. Lewis, B.E., Wallis, D.E., Leya, F., Hursting, M.J., Kelton, J.G. & Argatroban, I. (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of Internal Medicine, 163, 1849-1856.
42. Lewis, B.E., Wallis, D.E., Hursting, M.J., Levine, R.L. & Leya, F. (2006) Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest, 129, 1407-1416.
43. Lindhoff-Last, E., Nakov, R., Misselwitz, F., Breddin, H.K. & Bauersachs, R. (2002) Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. British Journal of Haematology, 118, 1137-1142.
44. Lindhoff-Last, E., Kreutzenbeck, H.J. & Magnani, H.N. (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thrombosis and Haemostasis, 93, 63-69.
45. Linkins, L.A., Dans, A.L., Moores, L.K., Bona, R., Davidson, B.L., Schulman, S., Crowther, M. & American College of Chest, P (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest, 141, e495S-e530S.
46. Lo, G.K., Juhl, D., Warkentin, T.E., Sigouin, C.S., Eichler, P. & Greinacher, A. (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. Journal of Thrombosis and Haemostasis, 4, 759-765.
47. Lubenow, N., Hinz, P., Thomaschewski, S., Lietz, T., Vogler, M., Ladwig, A., Junger, M., Nauck, M., Schellong, S., Wander, K., Engel, G., Ekkernkamp, A. & Greinacher, A. (2010) The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood, 115, 1797-1803.
48. Magnani, H.N., Beijering, R.J.R. & ten Cate, J.W. (1997) Orgaron anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: New Anticoagulants for the Cardiovascular Patient (ed. by R. Pifarre), pp. 487-500. Hanley & Belfus, Phiadelphia.
49. Mahaffey, K.W., Lewis, B.E., Wildermann, N.M., Berkowitz, S.D., Oliverio, R.M., Turco, M.A., Shalev, Y., Ver Lee, P., Traverse, J.H., Rodriguez, A.R., Ohman, E.M., Harrington, R.A., Califf, R.M. & Investigators, A. (2003) The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. The Journal of Invasive Cardiology, 15, 611-616.
50. Martel, N., Lee, J. & Wells, P.S. (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood, 106, 2710-2715.
51. Mertzlufft, F., Kuppe, H. & Koster, A. (2000) Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function. Journal of Cardiothoracic and Vascular Anesthesia, 14, 304-308.
52. Morel-Kopp, M.C., Tan, C.W., Brighton, T.A., McRae, S., Baker, R., Tran, H., Mollee, P., Kershaw, G., Joseph, J. & Ward, C., for the ASTH Clinical Trials Group. (2012) Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thrombosis and Haemostasis, 107, 575-583.
53. Nader, N.D., Khadra, W.Z., Reich, N.T., Bacon, D.R., Salerno, T.A. & Panos, A.L. (1999) Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Annals of Thoracic Surgery, 68, 1640-1643.
54. Nellen, V., Sulzer, I., Barizzi, G., Lammle, B. & Alberio, L. (2012) Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1291 patients. Haematologica, 97, 89-97.
55. Nuttall, G.A., Oliver, Jr, W.C., Santrach, P.J., McBane, R.D., Erpelding, D.B., Marver, C.L. & Zehr, K.J. (2003) Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesthesia and Analgesia, 96, 344-350.
56. Poetzsch, B. & Madlener, K. (2004) Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia (ed. by T.E. Warkentin & A. Greinacher), pp. 531-551. Marcel Dekke, New York.
57. Pohl, C., Kredteck, A., Bastians, B., Hanfland, P., Klockgether, T. & Harbrecht, U. (2005) Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology, 64, 1285-1287.
58. Potzsch, B., Klovekorn, W.P. & Madlener, K. (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. New England Journal of Medicine, 343, 515.
59. Pouplard, C., Amiral, J., Borg, J.Y., Vissac, A.M., Delahousse, B. & Gruel, Y. (1997) Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. British Journal of Haematology, 99, 273-280.
60. Pouplard, C., Gueret, P., Fouassier, M., Ternisien, C., Trossaert, M., Regina, S. & Gruel, Y. (2007) Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 5, 1373-1379.
61. Prandoni, P., Siragusa, S., Girolami, B. & Fabris, F. (2005) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood, 106, 3049-3054.
62. Qian, Y., Pan, J., Zhou, X., Weiser, P., Lu, H. & Zhang, L. (2010) Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Progress in Molecular Biology and Translational Science, 93, 395-421.
63. Sachs, U.J., von Hesberg, J., Santoso, S., Bein, G. & Bakchoul, T. (2011) Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thrombosis and Haemostasis, 106, 1197-1202.
64. Schenk, J.F., Pindur, G., Stephan, B., Morsdorf, S., Mertzlufft, F., Kroll, H., Wenzel, E. & Seyfert, U.T. (2003) On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 9, 25-32.
65. Selleng, S., Malowsky, B., Strobel, U., Wessel, A., Ittermann, T., Wollert, H.G., Warkentin, T.E. & Greinacher, A. (2010) Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. Journal of Thrombosis and Haemostasis, 8, 30-36.
66. Sheridan, D., Carter, C. & Kelton, J.G. (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood, 67, 27-30.
67. Smythe, M.A., Warkentin, T.E., Stephens, J.L., Zakalik, D. & Mattson, J.C. (2002) Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 71, 50-52.
68. Tanimura, K., Ebina, Y., Sonoyama, A., Morita, H., Miyata, S. & Yamada, H. (2012) Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency. The Journal of Obstetrics and Gynaecology Research, 38, 749-752.
69. Tardy-Poncet, B., Tardy, B., Reynaud, J., Mahul, P., Mismetti, P., Mazet, E. & Guyotat, D. (1999) Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest, 115, 1616-1620.
70. Walenga, J.M., Jeske, W.P., Wood, J.J., Ahmad, S., Lewis, B.E. & Bakhos, M. (1999) Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Seminars in Hematology, 36, 22-28.
71. Warkentin, T.E. (1996) Heparin-induced skin lesions. British Journal of Haematology, 92, 494-497.
72. Warkentin, T.E. (2003) Heparin-induced thrombocytopenia: pathogenesis and management. British Journal of Haematology, 121, 535-555.
73. Warkentin, T.E. (2005) New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest, 127, 35S-45S.
74. Warkentin, T.E. & Greinacher, A. (2003) Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 76, 2121-2131.
75. Warkentin, T.E. & Greinacher, A. (2004a) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, 311S-337S.
76. Warkentin, T.E. & Greinacher, A. (2004b) Laboratory testing for heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia (ed. Warkentin T.E. & Greinacher A.), pp. 271-311. Marcel Dekker, New York.
77. Warkentin, T.E. & Heddle, N.M. (2003) Laboratory diagnosis of immune heparin-induced thrombocytopenia. Current Hematology Reports, 2, 148-157.
78. Warkentin, T.E. & Kelton, J.G. (1996) A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 101, 502-507.
79. Warkentin, T.E. & Kelton, J.G. (2001) Temporal aspects of heparin-induced thrombocytopenia. New England Journal of Medicine, 344, 1286-1292.
80. Warkentin, T.E. & Koster, A. (2005) Bivalirudin: a review. Expert Opinion on Pharmacotherapy, 6, 1349-1371.
81. Warkentin, T.E., Hayward, C.P., Smith, C.A., Kelly, P.M. & Kelton, J.G. (1992) Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. Journal of Laboratory and Clinical Medicine, 120, 371-379.
82. Warkentin, T.E., Elavathil, L.J., Hayward, C.P., Johnston, M.A., Russett, J.I. & Kelton, J.G. (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Annals of Internal Medicine, 127, 804-812.
83. Warkentin, T.E., Sheppard, J.A., Horsewood, P., Simpson, P.J., Moore, J.C. & Kelton, J.G. (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 96, 1703-1708.
84. Warkentin, T.E., Roberts, R.S., Hirsh, J. & Kelton, J.G. (2003) An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine, 163, 2518-2524.
85. Warkentin, T.E., Sheppard, J.A., Moore, J.C., Moore, K.M., Sigouin, C.S. & Kelton, J.G. (2005a) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? Journal of Laboratory and Clinical Medicine, 146, 341-346.
86. Warkentin, T.E., Cook, R.J., Marder, V.J., Sheppard, J.A., Moore, J.C., Eriksson, B.I., Greinacher, A. & Kelton, J.G. (2005b) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 106, 3791-3796.
87. Warkentin, T.E., Greinacher, A., Koster, A. & Lincoff, A.M. (2008a) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 340S-380S.
88. Warkentin, T.E., Makris, M., Jay, R.M. & Kelton, J.G. (2008b) A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. American Journal of Medicine, 121, 632-636.
89. Warkentin, T.E., Pai, M., Sheppard, J.I., Schulman, S., Spyropoulos, A.C. & Eikelboom, J.W. (2011) Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. Journal of Thrombosis and Haemostasis, 9, 2389-2396.
90. Whitlatch, N.L., Kong, D.F., Metjian, A.D., Arepally, G.M. & Ortel, T.L. (2010) Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood, 116, 1761-1766.
91. Young, S.K., Al-Mondhiry, H.A., Vaida, S.J., Ambrose, A. & Botti, J.J. (2008) Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature. Pharmacotherapy, 28, 1531-1536.
92. Zwicker, J.I., Uhl, L., Huang, W.Y., Shaz, B.H. & Bauer, K.A. (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2, 2133-2137.